FLNA NASDAQ
Filana Therapeutics, Inc.
1W: +24.4%
1M: +8.6%
3M: -25.5%
YTD: -59.9%
$0.93
-0.03 (-3.53%)
Weekly Expected Move ±25.1%
$0
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
Articles (1)
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (11)
Filana CEO buys 306,813 shares
Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy
Cassava Sciences GAAP EPS of -$0.18 beats by $0.05
Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update
Filana Therapeutics Reports Q1 2026 Financial Results and Business Update
Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII
Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII
Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data
Cassava Sciences GAAP EPS of -$0.26
Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results